PF 3654746

Drug Profile

PF 3654746

Alternative Names: PF 0354746; PF-03654746; PF-3654746

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Pfizer
  • Class Amides; Antihistamines; Cyclobutanes; Neuropsychotherapeutics; Pyrrolidines; Small molecules
  • Mechanism of Action Histamine H3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Allergic rhinitis; Alzheimer's disease; Attention-deficit hyperactivity disorder; Gilles de la Tourette's syndrome; Narcolepsy

Most Recent Events

  • 10 May 2012 Discontinued - Phase-II for Gilles de la Tourette's syndrome in USA (PO)
  • 24 Jan 2012 Phase-II clinical trials in Gilles de la Tourette's syndrome in USA (PO)
  • 28 Feb 2011 Discontinued - Phase-I for Alzheimer's disease in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top